2016 - Present | Chairman, Providence ‐ Pacific Neuroscience Institute Medical Group | |
|
||
2016 - Present | Director and Founder, Providence ‐ Pacific Neuroscience Institute | |
|
||
2016 - Present | President and CEO, Providence ‐ Pacific Neuroscience Institute Foundation | |
|
||
2014 - Present | Member, Board of Directors, Providence ‐ Providence Saint John’s Health Center | |
|
||
2013 - Present | Professor of Neuroscience & Neurosurgery, Providence ‐ John Wayne Cancer Institute | |
|
||
2010 - Present | Chief, Providence ‐ Division of Neurosurgery, Saint John’s Health Center | |
|
||
2007 - Present | Director, Providence ‐ Pacific Brain Tumor Center & Pituitary Disorders Center | |
|
Disciplines
Grants
2012 - 2015 | A pilot study of pre- & post-operative Somatuline Depot therapy in acromegalic patients treated by endonasal endoscopic surgery: impact on early remission rate and perioperative morbidity |
Ipsen | |
Role: Principal Investigator | |
2008 - 2012 | Hypopituitarism in Retired Professional Football Players |
National Operating Committee on Standards for Athletic Equipment (NOCSAE) | |
Role: Co-Principal Investigator | |
2006 - 2009 | Rosiglitazone: novel therapy for pituitary tumors (Phase II) |
NIH/FDA R01 - FD003096 | |
Role: Co-Investigator | |
Colleague(s): Principal Investigator: Anthony Heaney MD, Ph.D | |
2002 - 2008 | Hypopituitarism after Moderate and Severe Head Injury |
NINDS/NIH - Grant # R01 NS 40777 | |
Role: Principal Investigator | |
2002 - 2006 | Acute Secondary Adrenal Insufficiency after Moderate and Severe Head Injury |
NIH - Grant # K23 RR 1729801 | |
Role: Co-Mentor | |
Colleague(s): Principal Investigator: Pejman Cohan, M.D | |
2002 - 2005 | Hypopituitarism after Moderate and Severe Head Injury |
Pfizer | |
Role: Principal Investigator | |
1998 - 2003 | Project 1- “Incidence, Time Course, and Pathophysiology of Hyperglycolysis Following Human Traumatic Brain Injury” |
UCLA Program Project Grant | |
Neurometabolic Pathobiology of Traumatic Brain Injury | |
Role: Co-Principal Investigator | |
Colleague(s): Program Director: Donald Becker, M.D. | |
2000 | Hypopituitarism Following Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage |
Pharmacia & Upjohn | |
Role: Principal Investigator | |
Colleague(s): Co-investigators: Pejman Cohan, M.D., Irene T. Gaw Gonzalo, M.D., Ronald Swerdloff, M.D. and Christina Wang, M.D. | |
1999 | Hypopituitarism Following Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage |
Stein-Oppenheimer Endowment Awards | |
Role: Principal Investigator | |
Colleague(s): Co-investigators: Ronald Swerdloff, M.D. Christina Wang, M.D., Irene T. Gaw Gonzalo, M.D., Mohammad Saad M.D. | |
1999 | Post-traumatic Impairment of Cerebral Vasoreactivity |
Zeneca Pharmaceuticals | |
Role: Principal Investigator | |
1998 | Hypopituitarism Following Moderate and Severe Traumatic Brain Injury |
Genentech Foundation for Growth and Development | |
Role: Co-Principal Investigator | |
Colleague(s): Co-investigators: Ronald Swerdloff, M.D. Christina Wang, M.D., Irene T. Gaw Gonzalo, M.D. | |
1997 - 1998 | A Randomized Placebo-Controlled Study of CI-1009 in Severe Head Injury Patients |
Parke-Davis Pharmaceuticals | |
Role: Principal Investigator | |
1993 - 1997 | A randomized, stratified, double-blind, multi-center study of the efficacy and safety of Sygen vs placebo following standard methylprednisolone therapy in the treatment of acute spinal cord injury |
Fidia Pharmaceutical Company | |
Role: Co-Investigator | |
Colleague(s): PI: Duncan McBride | |
1993 - 1997 | Project 3 – “Post-Traumatic Cerebral Arterial Spasm |
National Institute Neurologic Disease and Stroke | |
UCLA Brain Injury Research Center. Program Project Grant. | |
Role: Key Investigator | |
Colleague(s): Program Director: Donald P. Becker, M.D. | |
1996 | Efficacy of 6 versus 10 mg of tirilazad mesylate in male patients with aneurysmal subarachnoid hemorrhage |
The Upjohn Company | |
Role: Principal Investigator | |
1995 - 1996 | Efficacy/Safety of 15 mg/kg/day Tirilazad Mesylate in North American Women with Subarachnoid hemorrhage |
The Upjohn Company | |
Role: Principal Investigator | |
1994 - 1994 | Dose escalation study of tirilazad mesylate in moderate and severe head injured patients |
The Upjohn Company | |
Role: Principal Investigator | |
1993 - 1994 | Dose escalation study of tirilazad mesylate in moderate and severe head injured patients |
The Upjohn Company | |
Role: Co-investigator | |
Colleague(s): PI: Michael Caron |
Professional Service and Affiliations
Member, American Association of Clinical Endocrinologists, Pituitary Scientific Committee | Member, American Association of Neurological Surgeons | Member, American Medical Association | Member, Congress of Neurological Surgeons | Member, Foundation for International Education in Neurological Surgery | Member, International Society of Pituitary Surgeons | Editorial Review Board, Ad hoc reviewer, Minimally Invasive Neurosurgery, Neuro-Oncology | Editorial Review Board, Neurosurgery | Member, North American Skull Base Society | Member, Society for Neuro-Oncology | Member, The Endocrine Society | Member, The Pituitary Society | Editorial Review Board, World Neurosurgery |
1993 | Neurosurgical Residency Training, George Washington University Medical Center, Washington, D.C. | |
|
||
1987 | Surgical Internship, St. Vincent's Hospital and Medical Center, New York, NY | |
|
||
1986 | MD, Georgetown University ‐ School of Medicine | |
|
||
1982 | BA, Claremont Men's College ‐ Biology and Chemistry | |
|